title: Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report.
abstract: Uterine carcinosarcoma (malignant mixed Mullerian tumor) is an uncommon female genital tract neoplasm characterized by an admixture of epithelial and stromal malignant cells. We report a case of 50-year-old peri-menopausal woman diagnosed to have early-stage (IB due to FIGO) uterine carcinosarcoma of the homologous type with superficial (3mm) myo-invasion. The patient showed no clinical symptoms of the disease and had no family history of female genital tract malignancies. Positive immunostaining for steroid receptors (estrogen-alpha and progesterone receptors), cytokeratin, and EGFR was detected only in the carcinomatous area, whereas beta-catenin, BCL-2, COX-2, p16(INK4a), PTEN, RB-1, and vimentin were immunoreactive in both components. Androgen receptor, CD10, desmin, HER-2/neu, and P53 were found to be negative either in the carcinomatous or in the sarcomatous area. Tumor proliferative activity was higher in the carcinomatous (25%) than in the sarcomatous (2%) component. Based on these findings, immunohistochemical evaluation of multiple receptor status in the carcinomatous and sarcomatous areas of carcinosarcoma may provide a clue to the pathogenesis and hormonal receptor status of this uncommon uterine malignancy.
authors.affiliation: IInd Department of Gynecology, Lublin University School of Medicine, 8 Jaczewski Street, 20-954 Lublin, Poland. andrzej.semczuk@am.lublin.pl
authors.forename: Andrzej
authors.initials: A
authors.lastname: Semczuk
authors.forename: Danuta
authors.initials: D
authors.lastname: Skomra
authors.forename: Monika
authors.initials: M
authors.lastname: Chyzyńska
authors.forename: Wiktor
authors.initials: W
authors.lastname: Szewczuk
authors.forename: Piotr
authors.initials: P
authors.lastname: Olcha
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Korobowicz
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D002296:Carcinosarcoma / Q000378:metabolism* / Q000473:pathology*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000096:biosynthesis; D051546:Cyclooxygenase 2 / Q000096:biosynthesis; D066246:ErbB Receptors / Q000096:biosynthesis; D047628:Estrogen Receptor alpha / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000096:biosynthesis; D008875:Middle Aged; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis; D016160:Retinoblastoma Protein / Q000096:biosynthesis; D014594:Uterine Neoplasms / Q000378:metabolism* / Q000473:pathology*; D014746:Vimentin / Q000096:biosynthesis; D051176:beta Catenin / Q000096:biosynthesis
chemical_list: D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16; D047628:Estrogen Receptor alpha; D019253:Proto-Oncogene Proteins c-bcl-2; D011980:Receptors, Progesterone; D016160:Retinoblastoma Protein; D014746:Vimentin; D051176:beta Catenin; D007633:Keratins; D051546:Cyclooxygenase 2; D066246:ErbB Receptors; D051059:PTEN Phosphohydrolase